Premium
Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin
Author(s) -
O'Neill B.,
Callaghan N.,
Stapleton M.,
Molloy W.
Publication year - 1982
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1982.tb03067.x
Subject(s) - phenytoin , carbamazepine , cholesterol , medicine , endocrinology , high density lipoprotein , epilepsy , anticonvulsant , lipoprotein , free fraction , drug , pharmacology , pharmacokinetics , psychiatry
Serum lipids and the cholesterol concentration in the high density lipoprotein (HDL) fraction were measured in epileptic patients taking either carbamazepine or phenytoin as single drug treatment. There was a significant increase in HDL‐cholesterol levels in patients taking both phenytoin and carbamazepine. Serum total‐cholesterol concentrations in patients taking both drugs did not differ significantly from those of controls. The ratio of HDL‐cholesterol/total cholesterol was increased in both drugs and the increase reached significance in patients taking phenytoin. There was a significant increase in serum triglycerides in females taking carbamazepine.